• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by BriaCell Therapeutics Corp.

    1/3/25 5:00:20 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under §240.14a-12

     

    BriaCell Therapeutics Corp.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☐ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     
     

     

     

    Suite 300 – 235 15th Street

    West Vancouver, BC V7T 2X1

     

    January 3, 2025

     

    NOTICE OF NEW DATE FOR RESCHEDULED

    2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

     

    To the shareholders of BriaCell Therapeutics Corp.:

     

    The 2025 Annual General Meeting of Shareholders (the “Meeting”) of BriaCell Therapeutics Corp. (the “Company”) originally scheduled to be held on Thursday, January 23, 2025, has been has been rescheduled and will now be held on Wednesday, February 5, 2025, at 9:00 a.m. Eastern Time at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the rescheduled Meeting. The Meeting has been rescheduled due to delays stemming from the disruption in postal service in Canada, and to provide further time to solicit proxies from the Company’s shareholders.

     

    Shareholders who have already cast their votes do not need to take any action, unless they wish to change or revoke their prior proxy or voting instructions, and their votes will be counted at the rescheduled Meeting. For shareholders who have not yet cast their votes, we urge them to vote their shares now, so they can be tabulated prior to the rescheduled Meeting. Completed and signed proxies and non-objecting beneficial owners and voting instruction forms must be received by Computershare by 9:00 a.m. Eastern Time on February 3, 2025.

     

    The Company filed its Proxy Statement for the Meeting (the “Proxy Statement”) on December 17, 2024: (i) under the company’s profile on EDGAR with the Securities and Exchange Commission at https://www.sec.gov, (ii) under the Company’s profile on SEDAR+ at https://www.sedarplus.ca/ (“SEDAR+”) and (iii) on the Company’s website at https://investors.briacell.com/filings-shareholder-information. The Proxy Statement should be read in conjunction with this notice. To the extent information in this notice updates or conflicts with information contained in the Proxy Statement, the information in this notice is the more current information. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ANY OTHER RELEVANT MEETING DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR MAY CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION.

     

    Other than the date of the Meeting, deadlines for receipt of signed proxies and voting instruction forms or as set forth herein with respect to Participants in the Solicitation, there is no change to the Proxy Statement filed with the Securities and Exchange Commission on December 17, 2024 or the proxy card mailed, which is attached hereto.

     

    Participants in the Solicitation

     

    The Company and its directors and executive officers and other employees may be deemed to be participants in the solicitation of proxies in respect of the Meeting. The Company has also engaged Morrow Sodali (Canada) Ltd. (“Morrow”), a proxy solicitation firm, to assist management in the solicitation of proxies and governance advisory services in connection with the Meeting. The Company will pay Morrow a fee of $25,000, additional fees per inbound/outbound telephone call, and reasonable out-of-pocket expenses. Our engagement letter with Morrow contains confidentiality, indemnification and other provisions that the Company believes are customary for this type of engagement. Our directors and officers may also solicit proxies by telephone, facsimile, mail, Internet, or in person. They will not be paid any additional amounts for soliciting proxies. We may also request that intermediaries, brokerage firms, nominees, custodians and fiduciaries transmit materials related to the Meeting to the non-registered holders, and we will reimburse them for their reasonable out-of-pocket expenses in transmitting such materials.

     

    Information About the Meeting

     

    The Meeting will address the following: receipt of audited financial statements and auditor’s report, election of directors for the coming year, and appointment of the auditor and setting their remuneration. The Company’s Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company’s proxy statement for the Meeting. Institutional Shareholder Services Inc. has released its recommendation that shareholders vote FOR the proposals, as well.

     

     
     

     

    How Registered Shareholders Can Vote

     

    Registered shareholders are shareholders who hold their shares directly in the Company, and not through a brokerage account or depository company. Registered shareholders can call Computershare Shareholder Services at 1-800-564-6253 (Canada/US) or for overseas holders, call direct dial number 1-514-982-7555 (Monday to Friday, 8:30am to 8:00pm EST) to request their voting control numbers.

     

    How Beneficial Shareholders Can Vote

     

    Beneficial shareholders are shareholders who hold their investment through a brokerage house, depository company or other intermediary. There are two types of beneficial owners: (i) those who object to their identity being made known to the issuers of securities which they own (“Objecting Beneficial Owners” or “OBOs”), and (ii) those who do not object to their identity being made known to the issuers of securities which they own (“Non-Objecting Beneficial Owners” or “NOBOs”). The Company has arranged to send Meeting Materials directly to NOBOs. NOBOs may submit their votes by completing the Voting Instruction Form (“VIF”) available on the Company’s website and sending the completed VIF to Computershare by email at [email protected]. NOBOs can also contact Computershare at 1-800-564-6253 to request their voting control numbers and instructions. OBOs should contact their brokerage house or depository company or other intermediary and ask to obtain their voting control number and instructions.

     

    Shareholders are strongly encouraged to vote via telephone or internet at:

     

    ●Online: www.investorvote.com
    ●Toll-Free Telephone: 1-866-732-VOTE (8683)

     

    Investor Questions and Assistance

     

    Shareholders who have questions or require assistance with voting their proxy may contact the Company’s proxy solicitation agent, Sodali, at:

     

    ●North American Toll-Free Number: 1-888-444-0591
    ●Outside North America (collect calls accepted): 1-289-695-3075
    ●Email: [email protected]

     

     
     

     

     

     
     

     

     

     

     

    Get the next $BCTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

    SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)

    1/23/26 6:59:18 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

    1/15/26 4:15:57 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by BriaCell Therapeutics Corp.

    424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)

    1/14/26 4:15:34 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

    Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvem

    1/28/26 7:30:00 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

    9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchma

    1/27/26 7:30:00 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Therapeutics Announces Closing of US$30 million Public Offering

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit was sold to the public at a price of US$5.59 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately US$30 million, before deduct

    1/15/26 4:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

    2/14/22 6:04:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 4:38:08 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Williams William V.

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 3:22:52 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

    PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

    2/5/25 6:15:47 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

    1/3/25 5:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

    PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

    12/17/24 4:05:59 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

    The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

    7/7/23 8:10:00 AM ET
    $BCTX
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/12/24 6:06:07 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/10/24 6:06:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/5/24 7:45:06 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care